Charu Aggarwal, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data updates from the ADAURA trial, an overall survival analysis of osimertinib in non–small cell lung cancer (NSCLC).
Defining Earlier Use of Immunotherapy in Patients With NSCLC
In the non–small cell lung cancer space, identifying the appropriate candidate to receive perioperative approaches, such as neoadjuvant or adjuvant therapy, remains the clinical objective.
Read More
Strategies for Neoadjuvant NSCLC Treatment
In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.
Listen
CAN-2409 Combination Elicits Encouraging Survival Results in NSCLC
Treatment with CAN-2409 produced promising survival data and continues to show a favorable safety and tolerability profile for the treatment of non-resectable, stage III/IV non–small cell lung cancer.
Individualizing Immunotherapy in Non–Small Cell Lung Cancer
Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.
CheckMate-77T Update: Nivolumab-Based Regimen Improves EFS in NSCLC
In the phase 3 CheckMate-77T trial, a neoadjuvant and adjuvant treatment strategy including nivolumab and chemotherapy improved survival in resectable stage IIA to IIIB non–small cell lung cancer.
Pembrolizumab/Lenvatinib Shows No Survival Advantage in Metastatic, Nonsquamous NSCLC
The phase 3 LEAP-006 study of pembrolizumab plus lenvatinib and chemotherapy has missed its dual primary end points.